Metabolic reprograming confers tamoxifen resistance in breast cancer.
Chem Biol Interact
; 347: 109602, 2021 Sep 25.
Article
in En
| MEDLINE
| ID: mdl-34331906
ABSTRACT
Breast cancer is the most common cancer among females and the leading cause of cancer-related deaths. Approximately 70 % of breast cancers are estrogen receptor (ER) positive. An ER antagonist such as tamoxifen is used as adjuvant therapy in ER-positive patients. The major problem with endocrine therapy is the emergence of acquired resistance in approximately 40 % of patients receiving tamoxifen. Metabolic alteration is one of the hallmarks of cancer cells. Rapidly proliferating cancer cells require increased nutritional support to fuel various functions such as proliferation, cell migration, and metastasis. Recent studies have established that the metabolic state of cancer cells influences their susceptibility to chemotherapeutic drugs and that cancer cells reprogram their metabolism to develop into resistant phenotypes. In this review, we discuss the major findings on metabolic pathway alterations in tamoxifen-resistant (TAMR) breast cancer and the molecular mechanisms known to regulate the expression and function of metabolic enzymes and the respective metabolite levels upon tamoxifen treatment. It is anticipated that this in-depth analysis of specific metabolic pathways in TAMR cancer might be exploited therapeutically.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Tamoxifen
/
Breast Neoplasms
/
Drug Resistance, Neoplasm
Language:
En
Journal:
Chem Biol Interact
Year:
2021
Type:
Article
Affiliation country:
India